What Clinical Evidence Shows About Tirzepatide and Period Changes Clinical trials of tirzepatide (SURMOUNT series) documented menstrual abnormalities in a small percentage of participants, most commonly amenorrhea (absent periods) or oligomenorrhea (infrequent periods)
Similarly, liraglutide has been reported to decrease alcohol-induced dopamine release in the NAc, further supporting the role of GLP-1R activation in modulating dopaminergic neurotransmission associated with substance use [31]
less edema was observed and inflammatory cell numbers decreased
This means that to deliver equivalent therapeutic effects, oral versions require much higher doses, increasing costs and side effects while producing variable results depending on food intake, gastric pH, and individual metabolism
doi: 10.3892/ol.2021.13042 242 XiaoHXuXDuLLiXZhaoHWangZet al
Dose reduction or temporary pause If you experience consistent side effects that do not subside over time or become intolerable, your clinicians may reduce the dose of retatrutide or pause the treatment for some time